SCA
FOLD

Secor Capital Advisors’s Amicus Therapeutics FOLD Stock Holding History

Secor Capital Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-87,251
Closed -$1.32M – 524
2017
Q3 		$1.32M Buy
+87,251
New +$1.15M 0.13% 235
2017
Q1 		– Sell
-25,409
Closed -$126K – 504
2016
Q4 		$126K Buy
+25,409
New +$176K 0.02% 474
2016
Q3 		– Sell
-75,692
Closed -$414K – 568
2016
Q2 		$414K Buy
+75,692
New +$529K 0.05% 436

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Secor Capital Advisors's FOLD Position: Q4 2017 in Review

Secor Capital Advisors sold out of Amicus Therapeutics (FOLD) in Q4 2017, closing a stake of 87,251 shares — an estimated $1.32M sold.

Secor Capital Advisors first reported a position in FOLD in Q2 2016 and held it in 3 quarters. The position peaked at $1.32M in Q3 2017. 185 funds tracked by Wall St. Rank hold FOLD as of Q4 2017.

  • Secor Capital Advisors reported no remaining Amicus Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Secor Capital Advisors sold 87,251 Amicus Therapeutics shares in Q4 2017, an estimated $1.32M.
  • Secor Capital Advisors first reported a position in Amicus Therapeutics in Q2 2016 and held it in 3 quarters.
  • Secor Capital Advisors's Amicus Therapeutics position peaked at $1.32M in Q3 2017.
  • 185 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2017.

Based on Secor Capital Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.